These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32206324)

  • 21. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes.
    Yamada H; Kakei M; Hara K
    J Clin Med Res; 2018 Nov; 10(11):838-842. PubMed ID: 30344819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
    Pishdad R; Pishdad P; Pishdad GR
    Am J Med Sci; 2020 Apr; 359(4):212-217. PubMed ID: 32200914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
    Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
    Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
    Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP
    Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
    Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
    Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitiglinide for type 2 diabetes treatment.
    Phillippe HM; Wargo KA
    Expert Opin Pharmacother; 2013 Oct; 14(15):2133-44. PubMed ID: 23992284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus.
    Younas A; Riaz J; Chughtai T; Maqsood H; Younus S; Qasim M; Saim M; Qazi S; Khaliq M; Fatima M
    Cureus; 2021 Jan; 13(1):e13045. PubMed ID: 33680590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
    Ojima K; Kiyono Y; Kojima M
    Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):245-55. PubMed ID: 15467258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious hypoglycemia associated with misuse of repaglinide.
    Flood TM
    Endocr Pract; 1999; 5(3):137-8. PubMed ID: 15251685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
    Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
    Endocr J; 2010; 57(7):579-86. PubMed ID: 20467165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching.
    Ando T; Kondo M; Asada-Yamada Y; Kawai M; Asano-Hayami E; Hayami T; Motegi M; Ejima Y; Nagao E; Kasagi R; Nakai-Shimoda H; Asano S; Kato M; Yamada Y; Yura-Miura E; Ishikawa T; Sugiura-Roth Y; Kojima C; Naito E; Himeno T; Tsunekawa S; Kato Y; Nakamura J; Kamiya H
    Diabetol Int; 2024 Jan; 15(1):99-108. PubMed ID: 38264217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study.
    Takeshita Y; Takamura T; Kita Y; Takazakura A; Kato K; Isobe Y; Kaneko S
    BMJ Open Diabetes Res Care; 2015; 3(1):e000122. PubMed ID: 26336611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
    Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
    Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
    J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.